Treatment-resistant major depressive disorder
FBK-118 against placebo in treatment-resistant major depressive disorder. Sponsor: Fabrikam Neuroscience (fictional), CNS and psychiatry.
Every risk that applies to this study, scored after TransCelerate's risk assessment tool. The KRIs and QTLs tabs set out what watches each one.
This study carries 45 risks
They come from its protocol answers, its countries and the kinds of site it uses: nine score high and 16 medium. Of those, 16 are not yet watched by any KRI, KPI or QTL. A new KRI or a closer look there would lower the risk most.
| Score | Risk | Why it applies here | L×I×D | Watched by |
|---|---|---|---|---|
| 18High | Placebo or no-added-treatment control armPD-05, evidence grade B; design risk | What does the control arm receive? Placebo or no added treatment | 3×3×2 | QTL: stopped study treatment early |
| 18High | Competing trials for the same patientsEB-02, evidence grade A; design risk | How many competing trials recruit the same patients? Many, and the eligible pool is small | 3×2×3 | Nothing yet |
| 18High | Active comparator (against placebo) in registry dataPD-17, evidence grade B; design risk | What does the control arm receive? Placebo or no added treatment | 3×2×3 | Nothing yet |
| 18High | Academic and hospital sites, and sites new to the sponsor, take longer to activatePM-02, evidence grade B; design risk | Have most sites worked with the sponsor before? No, mostly new sites | 3×2×3 | Nothing yet |
| 18High | Fragmented, negotiated costing and contractingPOL-03, evidence grade A; country risk | United Kingdom: Costing and contracting were the longest start-up step; the national contract has shortened it · Spain: Site contracts took 117 days in 2016 and about 90 after national templates | 3×2×3 | Nothing yet |
| 18High | Ethics-committee structure (random CPP allocation, 40 Italian territorial committees, a central Polish committee, Denmark's timeliness)POL-20, evidence grade B; country risk | Poland: A central ethics committee reviews every study; its effect on timelines is not measured | 3×2×3 | Nothing yet |
| 18High | Investigator attrition and one-and-done investigatorsS-08, evidence grade C; site risk | Community hospital: 8% of sites · Site new to research: 45% of sites | 3×2×3 | Nothing yet |
| 18High | Competing trialsS-21, evidence grade B; design and site risk | How many competing trials recruit the same patients? Many, and the eligible pool is small · Academic medical centre: 8% of sites · Dedicated research centre: 18% of sites | 3×2×3 | Nothing yet |
| 18High | Competing trials at a siteSH-30, evidence grade D; design risk | How many competing trials recruit the same patients? Many, and the eligible pool is small | 3×2×3 | Nothing yet |
| 12Medium | Follow-up burden and durationEB-17, evidence grade C; design risk | How heavy is the visit and procedure schedule? Heavier than typical | 2×3×2 | QTL: missing primary endpoint data; QTL: lost to follow-up or withdrew consent |
| 12Medium | Comorbidity exclusionsPD-15, evidence grade B; design risk | Does the protocol exclude common comorbidities? Yes | 2×3×2 | QTL: ineligible patients randomised |
| 12Medium | Overestimated eligible pool (Lasagna's law)EB-01, evidence grade B; design risk | How many non-essential exclusions does the protocol carry? Three or more | 3×2×2 | Study KPIs |
| 12Medium | Blinded placebo-controlled design instead of open-labelEB-03, evidence grade A; design risk | Is the study blinded? Blinded | 2×2×3 | Nothing yet |
| 12Medium | Older adults under-enrolledPB-10, evidence grade A; design risk | Is there an upper age limit? Yes | 2×2×3 | Nothing yet |
| 12Medium | Blinded placebo-controlled against open designPD-06, evidence grade A; design risk | Is the study blinded? Blinded | 2×2×3 | Nothing yet |
| 12Medium | Washout periods and concomitant-medication exclusionsPD-09, evidence grade C; design risk | Is there a run-in or a washout longer than four weeks? Yes | 2×2×3 | Nothing yet |
| 12Medium | Run-in period before randomisationPD-10, evidence grade C; design risk | Is there a run-in or a washout longer than four weeks? Yes | 2×2×3 | Nothing yet |
| 12Medium | Decentralised elementsPD-20, evidence grade C; design risk | Are any visits done remotely or at home? Some visits | 2×2×3 | Nothing yet |
| 12Medium | Non-enrolling activated sitesS-01, evidence grade A; site risk | Site new to research: 45% of sites | 3×2×2 | Study KPIs |
| 12Medium | Site type: enrolment rateS-07, evidence grade C; design and site risk | What kind of sites will the study mostly use? Mostly independent sites and practices · Dedicated research centre: 18% of sites | 2×2×3 | Nothing yet |
| 12Medium | Sites declining new studies for lack of capacityS-26, evidence grade C; site risk | Dedicated research centre: 18% of sites | 2×2×3 | Nothing yet |
| 9Medium | Restrictive eligibility criteria and protocol complexityEB-04, evidence grade B; design risk | How many non-essential exclusions does the protocol carry? Three or more | 3×3×1 | KRI: screen failure above the study's; QTL: ineligible patients randomised |
| 9Medium | Eligibility criteria exclude patients (comorbidity, age, performance status, language)PB-02, evidence grade A; design risk | How many non-essential exclusions does the protocol carry? Three or more · Does the protocol exclude common comorbidities? Yes | 3×3×1 | KRI: screen failure above the study's; QTL: ineligible patients randomised |
| 9Medium | Restrictive eligibility criteria (organ function, brain metastases, prior or concurrent malignancy, HIV, laboratory thresholds, performance status)PD-01, evidence grade A; design risk | How many non-essential exclusions does the protocol carry? Three or more | 3×3×1 | KRI: screen failure above the study's; QTL: ineligible patients randomised |
| 9Medium | Number of eligibility criteria and complexity growthPD-02, evidence grade B; design risk | How many non-essential exclusions does the protocol carry? Three or more | 3×3×1 | KRI: screen failure above the study's; KRI: important protocol deviations; QTL: ineligible patients randomised |
| 6Low | Procedural and visit burden (visits, blood draws, questionnaires)PD-03, evidence grade B; design risk | How heavy is the visit and procedure schedule? Heavier than typical | 2×3×1 | KRI: important protocol deviations; QTL: missing primary endpoint data; QTL: lost to follow-up or withdrew consent; QTL: stopped study treatment early |
| 6Low | Protocol amendmentsEB-18, evidence grade B; design risk | How settled is the protocol? Likely to change | 1×2×3 | Nothing yet |
| 6Low | Patient and public involvement in designEB-23, evidence grade B; design risk | Did patients help design the protocol? No | 1×2×3 | Nothing yet |
| 6Low | Racial and ethnic under-representationPB-12, evidence grade A; country risk | United States: Under-represented groups need a plan from the start; diversity action plans apply to Phase III studies | 3×2×1 | KRI: enrolment against the diversity plan |
| 6Low | Substantial protocol amendmentsPD-04, evidence grade B; design risk | How settled is the protocol? Likely to change | 1×2×3 | Nothing yet |
| 6Low | No patient and public involvement in designPD-18, evidence grade A; design risk | Did patients help design the protocol? No | 1×2×3 | Nothing yet |
| 6Low | No upstream protocol feasibility reviewPD-21, evidence grade B; design risk | How settled is the protocol? Likely to change | 1×2×3 | Nothing yet |
| 6Low | The US activates its first site quickly but scales its site fleet slowlyPM-03, evidence grade B; country risk | United States: The first US site opens quickly, but the rest of the US sites open slowly | 3×2×1 | KRI: site activation overdue |
| 6Low | Regulator assessment backlogPOL-02, evidence grade A; country risk | United Kingdom: The regulator's backlog of 2023 was cleared, but could recur | 1×2×3 | Nothing yet |
| 6Low | Regional regulatory transition friction (EU CTR and CTIS)POL-15, evidence grade A; country risk | Spain: Applications go through the EU Clinical Trials Regulation and its portal · Poland: Applications go through the EU Clinical Trials Regulation and its portal | 3×2×1 | KRI: site activation overdue |
| 6Low | New-to-sponsor siteS-05, evidence grade B; design and site risk | Have most sites worked with the sponsor before? No, mostly new sites · Site new to research: 45% of sites | 3×2×1 | KRI: important protocol deviations |
| 6Low | Protocol amendments before and after activationS-14, evidence grade B; design risk | How settled is the protocol? Likely to change | 1×2×3 | Nothing yet |
| 6Low | Fewer physicians willing to be investigatorsS-30, evidence grade C; site risk | Community hospital: 8% of sites | 1×2×3 | Nothing yet |
| 4Low | Technology burdenS-18, evidence grade B; design risk | How many vendors and systems will sites use? Many, or new to sites | 2×2×1 | KRI: data entry lag; KRI: queries open over 30 days |
| 4Low | Protocol complexity and site burdenS-24, evidence grade B; design and site risk | How heavy is the visit and procedure schedule? Heavier than typical · Community specialist practice: 7% of sites | 2×2×1 | KRI: important protocol deviations |
| 3Low | Coordinator turnoverS-09, evidence grade B; site risk | Regional teaching hospital: 13% of sites · Community hospital: 8% of sites | 1×3×1 | KRI: data entry lag; KRI: queries open over 30 days |
| 3Low | Slow site payment and holdbacksS-17, evidence grade B; site risk | Community specialist practice: 7% of sites | 1×1×3 | Nothing yet |
| 2Low | Site type: activation speedS-06, evidence grade A; design and site risk | What kind of sites will the study mostly use? Mostly independent sites and practices · Academic medical centre: 8% of sites · Regional teaching hospital: 13% of sites | 1×2×1 | KRI: site activation overdue; Study KPIs |
| 2Low | Site capacity saturationS-11, evidence grade B; site risk | Academic medical centre: 8% of sites · Community specialist practice: 7% of sites | 1×2×1 | KRI: data entry lag |
| 2Low | Start-up: contracts and budgetsS-12, evidence grade A; site risk | Academic medical centre: 8% of sites · Regional teaching hospital: 13% of sites | 1×2×1 | KRI: site activation overdue; Study KPIs |
How the scores are worked out
- Likelihood. From the answer that switched the risk on: 3 if it cuts the recruitment rate to ×0.75 or below, 2 if it cuts it at all or changes screening or retention, 1 otherwise. From the risk's scope in the country: 3 if it touches all of the country's sites, 2 if some, 1 if only should an event recur. From the share of the study's sites whose profile carries the risk: 3 at 40% or more, 2 at 15% or more, 1 below.
- Impact. Scores 3 if the risk threatens the result, the patients' safety or their rights; 1 if it mainly adds cost; 2 for everything else, which mostly delays recruitment.
- Detectability. Scores 1 if a site-level KRI watches the risk every month, 2 if only a study-level KPI or QTL does, 3 if nothing does. A watched risk scores lower, so adding a KRI lowers the score.
- Bands. High from 18, medium from 8, out of 27.
- Method after TransCelerate RACT (2013); rules and cut-offs are epiClinical assumptions.